Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2011

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

sunitinib, docetaxel, cisplatin

"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"

Trial Locations (1)

110

RECRUITING

Section of Hematology, Department of Medicine,Taipei Medical University Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

TTY Biopharm

INDUSTRY

lead

Taipei Medical University Hospital

OTHER